2022 American Transplant Congress
Avoiding Cytomegalovirus Mismatching in Deceased Donor Kidney Allocation System in the US
*Purpose: Cytomegalovirus (CMV) mismatch, donor-positive/recipient-negative serostatus (D+/R-), carries a high risk of developing CMV infection, graft failure mortality. The current kidney allocation system (KAS) does…2022 American Transplant Congress
Seasonal Variation of Cytomegalovirus Infection in Kidney Transplant Recipients
University of Wisconsin Health, Madison, WI
*Purpose: Studies conducted in the northern United States found cytomegalovirus (CMV) disease after liver transplantation follows a seasonal pattern, with increased incidence in Fall and…2022 American Transplant Congress
Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants
Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC
*Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…2022 American Transplant Congress
Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study
*Purpose: In a Phase 3 study of MBV vs IAT (val/ganciclovir, foscarnet, or cidofovir) for refractory CMV infection (with/without resistance; R/R) in hematopoietic cell transplant…2022 American Transplant Congress
Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience
Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it's effect…2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…2022 American Transplant Congress
An Interventional Study Using Cell-Mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study
*Purpose: There are limited interventional studies using CMV cell-mediated immunity to guide the duration of antiviral prophylaxis. We aimed to use CMV CMI to guide…2022 American Transplant Congress
BK Polyomavirus and Cytomegalovirus Infections in Kidney Transplantation from Hepatitis C Positive Donors to Uninfected Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Transplantation of hepatitis C viremic (HCV) donor kidneys into uninfected recipients (D+/R-) is becoming more common in the United States. However, the long-term risks…2022 American Transplant Congress
Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients
1Ochsner Medical Center, New Orleans, LA, 2Xavier University, New Orleans, LA
*Purpose: The goal of this study was to compare the safety and efficacy of a delayed valganciclovir (VGCV) dosing protocol for cytomegalovirus (CMV) prophylaxis in…2021 American Transplant Congress
Murine Cytomegalovirus Induces Kidney Allograft Injury via Th17 Cells Recruited by Both Viral Antigen-Specific and Cytokine/chemokine Mediated Pathways
*Purpose: Cytomegalovirus infection in transplant recipients has been associated with renal allograft rejection and graft failure. We have previously shown that murine CMV (MCMV) infected…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 33
- Next Page »